Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma

On July 29, 2020

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

More than 1,800 customers in Texas assisted through Entergy’s The Power to Care program

Modification to Methodology of the S&P/CLX INTER

HII CEO Tours Company Operations in Hawaii and Meets with Military and Civilian Leaders